Latest news with #KomodoHealth
National Post
14-05-2025
- Health
- National Post
Komodo Health's Real-World Evidence Platform Drives 31 Patient Journey Research Studies at ISPOR 2025
Article content Comprehensive Patient Journey Data Links Clinical Outcomes to Real-World Impact, Addressing Critical Evidence Gaps in Oncology, Neurology, Cardiovascular, Metabolic, and Rare Diseases Article content Article content MONTREAL — Komodo Health today announced that its healthcare intelligence platform enabled 31 research studies being presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. These include three studies led by Komodo researchers and 27 collaborative studies with academic institutions, Life Sciences companies, and healthcare organizations. Article content 'The volume and diversity of research powered by our healthcare insights underscore the growing demand for high-quality real-world data combined with advanced analytical capabilities,' said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. 'By connecting individual patient journeys to large-scale health outcomes, we're enabling researchers to uncover actionable insights that improve clinical practice, healthcare policy, and patient outcomes.' Article content The ISPOR 2025 research presentations demonstrate the value of Komodo's real-world evidence across a wide range of therapeutic areas, including: Article content Oncology: Salix Pharmaceuticals, Analysis Group, and Bausch Health studied the economic burden of opioid-induced constipation among patients with or without cancer; Cardiovascular disease: Veradigm examined the discordance between apolipoprotein B and low-density lipoprotein cholesterol levels in predicting incident hypertension risk and how it correlates to differential hypertension development patterns between diabetic and non-diabetic populations; Metabolic disorders: Novo Nordisk studied non-invasive diagnostic approaches and earlier interventions for metabolic dysfunction-associated steatohepatitis (MASH); Neurology: Jazz Pharmaceuticals analyzed healthcare resource utilization and costs among individuals with narcolepsy or idiopathic hypersomnia (IH) who are considered at higher risk for negative clinical outcomes associated with sodium (due to underlying cardiovascular, cardiometabolic, or renal conditions); and Rare disease: Chiesi analyzed medical claims data to better understand healthcare resource utilization patterns among Fabry disease patients Article content Three poster presentations by Komodo researchers also showcase methodological advances: Article content Komodo provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, including lab results, genomics, and demographic information — through its platform to address fundamental challenges in health economics and outcomes research (HEOR). Whereas HEOR teams have traditionally relied on fragmented, incomplete datasets that provide only narrow snapshots of patients' in-network healthcare experiences, Komodo's platform enables researchers to link disparate datasets without the months typically spent on data cleaning and integration. The option to enhance disease understanding at the patient level with lab, EHR, patient insurance, race and ethnicity, and mortality data enables teams to self-serve cohort feasibility and insights. This ability accelerates study planning timelines by weeks and generates more accurate estimates of treatment patterns, healthcare resource utilization, and costs. Article content 'By closing critical data gaps and providing a patient-centric approach to HEOR, our powerful, all-in-one platform brings clean, connected, and compliant real-world data together,' Nathoo added. 'We eliminate the need for messy integrations, manual data wrangling, and coding cohorts from scratch, which enables HEOR teams to generate evidence faster. The inclusion of race, ethnicity, mortality, and other demographic insights at a near-census level also allows researchers to better model the clinical and financial impacts of new therapies across diverse populations, addressing the reality that disease burden is not borne equally across demographic groups.' Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Rowena Kelley 858.255.1651 media@ Article content Article content Article content
Business Wire
06-05-2025
- Business
- Business Wire
Komodo Health Partners with Nasdaq to Deliver First Integrated Healthcare-Specialized Data Insights to the Financial Services Industry
NEW YORK--(BUSINESS WIRE)--Komodo Health, the Evidentiary Standard for real-world data and healthcare analytics, today announced a partnership with Nasdaq Data to provide hedge funds, private equity, and venture capital firms with an in-depth view into the pharmaceutical and U.S. healthcare industries through the Nasdaq Medical Claims Insights (NMCI) dataset. 'Our partnership with Nasdaq Data provides market participants with a unique dataset that can sharpen their competitive edge across healthcare-related analysis and investing.' Miles Ennis, Chief Revenue Officer, Komodo Health Sourced from Komodo's Healthcare Map, the most comprehensive source of real-world data for understanding payer and provider trends, disease incidence, patient care, and prescribing patterns, NMCI will enable market participants to track trends in the pharmaceutical and healthcare industries, help forecast drug and company-level revenues, analyze shifts in market shares, and identify emerging drugs and companies. As an exclusive Nasdaq dataset, NMCI provides one of the most complete views of the U.S. healthcare system, tracking 330+ million longitudinal and real-time patient journeys across HCPs, HCOs, and sites of care. NMCI provides extensive information on patient journeys, including details on Rx, specialty pharmaceuticals, clinical records, electronic health and medical records, payers, labs, and more. This data is de-identified and does not include any personally identifiable information. 'Our partnership with Nasdaq Data provides market participants with a unique dataset that can sharpen their competitive edge across healthcare-related analysis and investing,' said Miles Ennis, Chief Revenue Officer, Komodo Health. 'Accessed through our AI-powered platform, users are provided with unparalleled breadth, quality, and coverage that can help inform decisions in an increasingly dynamic market.' 'Komodo's breadth, quality, and coverage of its insights combined with our data capabilities and innovation has unlocked a unique dataset that provides an in-depth view into the pharmaceutical and U.S. healthcare industries,' said Brandon Tepper, Senior Vice President and Global Head of Data at Nasdaq. 'The Nasdaq Medical Claims Insights will empower market participants to access new opportunities and drive more informed investment decisions and strategies.' Learn more about Nasdaq Medical Claims Insights. About Komodo Health Komodo is a healthcare insights and technology company that delivers the Evidentiary Standard for real-world data and analytics. By pairing the industry's most complete, unbiased view of patient encounters with AI-enabled and fit-for-purpose software, Komodo connects the dots between patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo delivers a velocity advantage by helping its customers accurately and efficiently access patient-centric insights at scale to drive faster decision-making, optimize workflows, close gaps in care, and help reduce the burden of disease. For more information, visit Nasdaq® is a registered trademark of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED. © 2025. Nasdaq, Inc. All Rights Reserved.
Yahoo
15-04-2025
- Business
- Yahoo
200+ Healthcare Industry Leaders Unite at Komodo Health's The One Day Summit to Accelerate Innovation Amid Disruption
Elite Forum Transforms Patient Care Through Real-World Evidence and AI Intelligence BOSTON, April 15, 2025--(BUSINESS WIRE)--Komodo Health will host its third-annual The One Day Summit, an exclusive gathering of more than 200 healthcare leaders and innovators in Life Sciences, biopharma, payer, and advocacy organizations, including speakers from Takeda Pharmaceuticals, Johnson & Johnson, Ipsen, Novartis Pharmaceuticals, and more. From real-world applications demonstrated by Komodo customers to C-suite discussions on navigating current industry challenges and anticipating future trends, the invitation-only event will showcase how the right evidence, delivered at the speed of innovation, is critical to driving transformative decisions in today's rapidly changing healthcare landscape. "Komodo's One Day Summit is a great opportunity to connect with others who are thinking deeply about how we use data to make better decisions," said Steve Davenport, Head of Commercial Data Management & Strategy at Takeda. "The event brings together a range of perspectives on the real challenges commercial teams are facing, and the conversations often spark new ideas that carry forward well beyond the day itself. In a space that's constantly evolving, having this kind of forum to share and learn is really valuable." Shaping the Future of Healthcare Together Set against the panoramic backdrop of Boston's skyline, The One Day Summit will take place April 23, 2025, at the State Room. Agenda highlights include: Accelerating Innovation Realizing a Velocity Advantage Adapting to the Evolving Data Landscape Amid Industry Disruption Innovating Clinical Trials With RWE and AI Navigating Data Change Management Connected Data and Analytics Ecosystem to Accelerate Insights "The need for transformative solutions that drive better patient outcomes has never been more critical," said Web Sun, Co-Founder and President of Komodo Health. "The One Day Summit represents our commitment to fostering a collaborative ecosystem where technology, data science, and healthcare expertise converge to address the industry's most pressing challenges. By bringing together this extraordinary community of innovators, we're not just discussing the future of healthcare — we're actively creating it." Sun and Komodo CEO and Co-Founder Arif Nathoo, MD, will keynote the event and will be joined by other thought leaders from across the healthcare spectrum, including: Asha Collins, Advisor, HealthX Ventures Ilker Oruc, Director, Commercial Analytics, Novartis Jennifer Wheeler, Immunology Medical Affairs Analytics, Johnson & Johnson Julie Tran, Senior Director, Commercial Analytics & Insights, Ipsen Lisa Arbogast, Industry Principal, Life Sciences, Snowflake Matt Goddeeris, Vice President of Discovery, Every Cure Sandy Leonard, Chief Commercial Officer, COTA Steve Davenport, Head of Commercial Data Management & Strategy, Takeda Setting a New Evidentiary Standard As Komodo celebrates over a decade of innovation in its mission to reduce the burden of disease, The One Day Summit will also spotlight how the company is setting the new standard for healthcare intelligence by pairing the industry's most complete, unbiased view of patient encounters with AI-enabled, fit-for-purpose software: Deeper, more contextualized insights: Komodo provides a comprehensive and complete view of the patient journey across healthcare providers, payers, and care settings in a single platform. Komodo's patient-centric approach to data curation and insight generation delivers the industry's richest, most accurate and granular insights. Value on day one: Customers realize value on day one with an AI-powered technology platform and software built on highly curated data products that empower all teams, regardless of technical skill level, with near real-time insights to drive consistency, collaboration, and efficiency across the enterprise. Innovation partner: Behind Komodo's unified approach is a team of experts, including physicians, healthcare data subject matter experts, data scientists, and clinical health informaticists, that helps customers solve their toughest data challenges and create innovative solutions. For more on The One Day Summit, visit About Komodo Health Komodo is a healthcare insights and technology company that delivers the Evidentiary Standard for real-world data and analytics. By pairing the industry's most complete, unbiased view of patient encounters with AI-enabled and fit-for-purpose software, Komodo connects the dots between patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo delivers a velocity advantage by helping its customers accurately and efficiently access patient-centric insights at scale to drive faster decision-making, optimize workflows, close gaps in care, and help reduce the burden of disease. For more information, visit View source version on Contacts Media Contact: Rowena Sign in to access your portfolio
Associated Press
15-04-2025
- Business
- Associated Press
200+ Healthcare Industry Leaders Unite at Komodo Health's The One Day Summit to Accelerate Innovation Amid Disruption
BOSTON--(BUSINESS WIRE)--Apr 15, 2025-- Komodo Health will host its third-annual The One Day Summit, an exclusive gathering of more than 200 healthcare leaders and innovators in Life Sciences, biopharma, payer, and advocacy organizations, including speakers from Takeda Pharmaceuticals, Johnson & Johnson, Ipsen, Novartis Pharmaceuticals, and more. From real-world applications demonstrated by Komodo customers to C-suite discussions on navigating current industry challenges and anticipating future trends, the invitation-only event will showcase how the right evidence, delivered at the speed of innovation, is critical to driving transformative decisions in today's rapidly changing healthcare landscape. 'Komodo's One Day Summit is a great opportunity to connect with others who are thinking deeply about how we use data to make better decisions,' said Steve Davenport, Head of Commercial Data Management & Strategy at Takeda. 'The event brings together a range of perspectives on the real challenges commercial teams are facing, and the conversations often spark new ideas that carry forward well beyond the day itself. In a space that's constantly evolving, having this kind of forum to share and learn is really valuable.' Shaping the Future of Healthcare Together Set against the panoramic backdrop of Boston's skyline, The One Day Summit will take place April 23, 2025, at the State Room. Agenda highlights include: 'The need for transformative solutions that drive better patient outcomes has never been more critical,' said Web Sun, Co-Founder and President of Komodo Health. 'The One Day Summit represents our commitment to fostering a collaborative ecosystem where technology, data science, and healthcare expertise converge to address the industry's most pressing challenges. By bringing together this extraordinary community of innovators, we're not just discussing the future of healthcare — we're actively creating it.' Sun and Komodo CEO and Co-Founder Arif Nathoo, MD, will keynote the event and will be joined by other thought leaders from across the healthcare spectrum, including: Setting a New Evidentiary Standard As Komodo celebrates over a decade of innovation in its mission to reduce the burden of disease, The One Day Summit will also spotlight how the company is setting the new standard for healthcare intelligence by pairing the industry's most complete, unbiased view of patient encounters with AI-enabled, fit-for-purpose software: For more on The One Day Summit, visit About Komodo Health Komodo is a healthcare insights and technology company that delivers the Evidentiary Standard for real-world data and analytics. By pairing the industry's most complete, unbiased view of patient encounters with AI-enabled and fit-for-purpose software, Komodo connects the dots between patient journeys and large-scale health outcomes. Across Life Sciences, payers, providers, and developers, Komodo delivers a velocity advantage by helping its customers accurately and efficiently access patient-centric insights at scale to drive faster decision-making, optimize workflows, close gaps in care, and help reduce the burden of disease. For more information, visit View source version on CONTACT: Media Contact: Rowena Kelley 858.255.1651 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH INSURANCE DATA MANAGEMENT OTHER HEALTH TECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES GENERAL HEALTH ARTIFICIAL INTELLIGENCE CLINICAL TRIALS SCIENCE BIOTECHNOLOGY SOFTWARE DATA ANALYTICS OTHER SCIENCE HEALTH SOURCE: Komodo Health Copyright Business Wire 2025. PUB: 04/15/2025 10:17 AM/DISC: 04/15/2025 10:17 AM
Al Jazeera
29-01-2025
- Health
- Al Jazeera
Trump signs order to defund gender transitions for LGBTQ youth
United States President Donald Trump has signed an executive order to halt the funding and promotion of gender transitions for LGBTQ youth. In his order signed on Tuesday, Trump said the federal government would no longer 'fund, sponsor, promote, assist, or support' gender transitions – also referred to as gender-affirming care – for those aged under 19. 'Countless children soon regret that they have been mutilated and begin to grasp the horrifying tragedy that they will never be able to conceive children of their own or nurture their children through breastfeeding,' the order said. 'Moreover, these vulnerable youths' medical bills may rise throughout their lifetimes, as they are often trapped with lifelong medical complications, a losing war with their own bodies, and, tragically, sterilization.' Trump's order covers a range of treatments and procedures for young people suffering from gender dysphoria – which describes the distress felt by people whose biological sex does not match their gender identity – including puberty blockers, cross-sex hormone therapy and surgery. The medical treatment of transgender youth has been a controversial and politically divisive issue in the US, where those calling for greater inclusion of LBGTQ youth have clashed with those expressing concern that minors are not mature enough to make decisions about potentially life-altering procedures. The number of young people diagnosed with gender dysphoria in the US has surged several-fold in recent years, though only a relatively small minority of those have undergone medical interventions, according to various analyses. An analysis by the Reuters news agency and health technology company Komodo Health found that 282 minors with a prior diagnosis of gender dysphoria underwent mastectomies in 2021. About 4,230 minors received cross-sex hormones and just under 1,400 received puberty blockers that same year, according to the analysis. Trump's order also directed agencies to end their reliance on guidance from the World Professional Association for Transgender Health, which it accused of peddling 'junk science.' GLADD, one of the biggest LGBTQ rights organisations in the US, blasted Trump's order, describing its rhetoric as 'appallingly inaccurate, incoherent, and extreme.' 'Health care for transgender people is supported by every major medical association. The Trump administration's unhinged obsession with attacking transgender people and their health care does not reflect medical fact and does not represent the reality of trans people, youth, and their freedom to be themselves, and make their own health care decisions, without being discriminated against and lied about,' GLADD said in a statement. 'The Trump administration's obsession comes at a high cost for every American who wants government to address actual issues like gun violence, abortion access, and rising costs.' Major US medical organisations, including the American Medical Association and American Academy of Pediatrics, have expressed support for gender-affirming care, though several European countries, including the UK, Sweden, Denmark, and France, have taken steps to roll back access to treatments such as puberty blockers. Last year, a landmark review commissioned by the UK's National Health Servic e concluded that the evidence behind medical treatments for youth with gender gender dysphoria was 'remarkably weak' and such interventions should only be taken with 'extreme caution'. Among other findings, the Cass Review said that puberty blockers were not found to relieve gender dysphoria or improve 'body satisfaction' and evidence about their effects on psychological wellbeing, cognitive development and fertility was insufficient or inconsistent.
